Patents by Inventor Marsel Scheer

Marsel Scheer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF USING BIOMARKERS AND CLINICAL VARIABLES FOR PREDICTING CHEMOTHERAPY BENEFIT
    Publication number: 20230116885
    Abstract: Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.
    Type: Application
    Filed: October 14, 2022
    Publication date: April 13, 2023
    Applicant: Myriad Genetics, Inc.
    Inventors: Alexander Gutin, Julia Reid, Ralf Kronenwett, Marsel Scheer
  • Method of using biomarkers and clinical variables for predicting chemotherapy benefit
    Patent number: 11505832
    Abstract: Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: November 22, 2022
    Assignee: MYRIAD GENETICS, INC.
    Inventors: Alexander Gutin, Julia Reid, Ralf Kronenwett, Marsel Scheer
  • METHOD OF USING BIOMARKERS AND CLINICAL VARIABLES FOR PREDICTING CHEMOTHERAPY BENEFIT
    Publication number: 20200283855
    Abstract: Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.
    Type: Application
    Filed: March 4, 2020
    Publication date: September 10, 2020
    Applicant: MYRIAD GENETICS, INC.
    Inventors: Alexander GUTIN, Julia REID, Ralf KRONENWETT, Marsel SCHEER
  • METHOD FOR DETERMINING THE RISK OF RECURRENCE OF AN ESTROGEN RECEPTOR-POSITIVE AND HER2-NEGATIVE PRIMARY MAMMARY CARCINOMA UNDER AN ENDOCRINE THERAPY
    Publication number: 20190010558
    Abstract: Provided herein are methods for predicting a result relating to breast cancer in a patient, the method comprising (a) determining the RNA expression levels of three or more of the following 8 genes in a tumor sample from the patient: UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST and MGP; and (b) mathematically combining the expression level values for the genes of the mentioned set to obtain a combined score, the combined score indicating a prognosis for the patient, wherein the RNA expression level values have at least in part not been normalized before the mathematical combination.
    Type: Application
    Filed: September 7, 2018
    Publication date: January 10, 2019
    Inventors: Karsten Weber, Marsel Scheer, Christoph Petry